Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

CELSA, Ciro
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.821
EU - Europa 785
AS - Asia 471
SA - Sud America 40
AF - Africa 9
OC - Oceania 5
Totale 3.131
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.811
IT - Italia 392
SG - Singapore 286
DE - Germania 181
CN - Cina 127
GB - Regno Unito 38
BR - Brasile 36
FI - Finlandia 36
AT - Austria 26
IE - Irlanda 25
SE - Svezia 18
HK - Hong Kong 14
NL - Olanda 14
IN - India 12
RO - Romania 11
RU - Federazione Russa 11
BE - Belgio 8
CA - Canada 7
CI - Costa d'Avorio 7
FR - Francia 6
JP - Giappone 6
AU - Australia 5
KR - Corea 5
CH - Svizzera 4
ES - Italia 3
LT - Lituania 3
PT - Portogallo 3
TR - Turchia 3
TW - Taiwan 3
BD - Bangladesh 2
IL - Israele 2
IQ - Iraq 2
UA - Ucraina 2
VE - Venezuela 2
VN - Vietnam 2
AE - Emirati Arabi Uniti 1
AF - Afghanistan, Repubblica islamica di 1
CL - Cile 1
CR - Costa Rica 1
CZ - Repubblica Ceca 1
EC - Ecuador 1
EG - Egitto 1
GE - Georgia 1
GR - Grecia 1
HU - Ungheria 1
LB - Libano 1
MX - Messico 1
NG - Nigeria 1
NI - Nicaragua 1
NO - Norvegia 1
NP - Nepal 1
OM - Oman 1
PK - Pakistan 1
Totale 3.131
Salva come PNG Salva come JPEG
Città #
Chandler 277
Singapore 236
Fairfield 211
Ashburn 155
Woodbridge 83
Palermo 80
Ann Arbor 68
Houston 68
Seattle 66
Wilmington 65
Altamura 63
New York 61
Medford 58
Santa Clara 52
Cambridge 45
Lawrence 36
Princeton 36
Rome 31
Helsinki 30
Ludwigshafen am Rhein 28
Bremen 27
Dublin 25
Des Moines 24
San Diego 21
Nuremberg 20
Beijing 19
London 15
Milan 14
Vienna 13
West Jordan 12
Columbus 10
Central 9
Brussels 8
Falkenstein 8
Krefeld 8
Venice 8
Abidjan 7
Boardman 7
Guangzhou 7
Pune 7
Cagliari 6
Florence 6
Nanjing 6
Amsterdam 5
Bologna 5
Changsha 5
Dallas 5
Dearborn 5
Gallarate 5
Hanover 5
Hong Kong 5
Kilburn 5
Lappeenranta 5
Los Angeles 5
Shenyang 5
Vicopisano 5
Jinan 4
Kumar 4
Messina 4
Ottawa 4
Verona 4
Washington 4
Zhengzhou 4
Aragona 3
Bari 3
Biancavilla 3
Catania 3
Edmond 3
Fasano 3
Forest City 3
Istanbul 3
Jiaxing 3
Nanchang 3
Naples 3
Saint Petersburg 3
Shanghai 3
Suwon 3
Sydney 3
Tokyo 3
Toronto 3
Aachen 2
Afragola 2
Baghdad 2
Barcellona Pozzo di Gotto 2
Basel 2
Clifton 2
Cologne 2
Cornuda 2
Council Bluffs 2
Erice 2
Frankfurt am Main 2
Gorgonzola 2
Ho Chi Minh City 2
Jundiaí 2
Las Palmas de Gran Canaria 2
Leawood 2
Mehlingen 2
Misterbianco 2
Mistretta 2
Munich 2
Totale 2.220
Salva come PNG Salva come JPEG
Nome #
Antidiabetic drugs in NAFLD: The accomplishment of two goals at once? 175
Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients with Non-alcoholic Fatty Liver Disease 152
Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients 133
Optimizing sequential systemic therapies for advanced hepatocellular carcinoma: A decision analysis 124
Pharmacological therapy of non-alcoholic fatty liver disease: What drugs are available now and future perspectives 118
Predicting in-hospital mortality from Coronavirus Disease 2019: A simple validated app for clinical use 117
The burden of hepatocellular carcinoma in non-alcoholic fatty liver disease: Screening issue and future perspectives 116
Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients 116
Risk Factors for Rate of Relapse and Effects of Steroid Maintenance Therapy in Patients With Autoimmune Pancreatitis: Systematic Review and Meta-analysis 102
Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma 92
Are radiological endpoints surrogate outcomes of overall survival in hepatocellular carcinoma treated with transarterial chemoembolization? 77
Competing-risk analysis of coronavirus disease 2019 in-hospital mortality in a Northern Italian centre from SMAtteo COvid19 REgistry (SMACORE) 75
Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study 67
Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer? 66
Diagnostic performance of endoscopic ultrasound through-the-needle microforceps biopsy of pancreatic cystic lesions: Systematic review with meta-analysis 66
Direct-acting antiviral agents and risk of hepatocellular carcinoma: is it still a clinical dilemma? 63
Impact of biliary stents on the diagnostic accuracy of EUS-guided fine-needle biopsy of solid pancreatic head lesions: A multicenter study 60
Biochemical biomarkers of NAFLD/NASH 58
First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials 57
Hepatectomy Versus Sorafenib in Advanced Nonmetastatic Hepatocellular Carcinoma: A Real-life Multicentric Weighted Comparison 56
Long-term evolution of LI-RADS observations in HCV-related cirrhosis treated with direct-acting antivirals 56
Systemic therapies for hepatocellular carcinoma: The present and the future 56
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment 55
Outcomes of hepatocellular carcinoma patients treated with sorafenib: A meta-analysis of Phase III trials 55
Reply 53
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: An individual patient data meta-analysis 51
Mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis: A validated prediction model 50
Dynamic angiopoietin-2 assessment predicts survival and chronic course in hospitalized patients with COVID-19 50
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy 49
Consequences of Extended Spectrum Beta-Lactamase–Producing Enterobacteriaceae and Methicillin-Resistant Staphylococcus aureus Carriage in Awaiting Liver Transplant Patients 48
Identification of clinical phenotypes and related survival in patients with large hccs 47
Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment 46
AGILE 3+ Score for the Diagnosis of Advanced Fibrosis and for Predicting Liver-related Events in NAFLD 45
Biliary complications after liver transplantation: current perspectives and future strategies 45
Direct-acting antiviral agents and risk of Hepatocellular carcinoma: Critical appraisal of the evidence 45
Efficacy of lumen-apposing metal stents or self-expandable metal stents for endoscopic ultrasound-guided choledochoduodenostomy: A systematic review and meta-analysis 45
RESIST-HCV Criteria to Monitor Progression of Low-Risk Esophageal Varices in Patients With Compensated Cirrhosis After HCV Eradication: The SIMPLE Study: SIMPLE: Scoring Index to Monitor Progression of Low-risk Esophageal varices 44
Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib 43
Radiomics Analysis on Gadoxetate Disodium-Enhanced MRI Predicts Response to Transarterial Embolization in Patients with HCC 41
Sicily Network for Liver Cancer: A Multidisciplinary Network Model for the Management of Primary Liver Tumors 41
Effect of pharmacological interventions and placebo on liver Histology in nonalcoholic steatohepatitis: A network meta-analysis 37
Surveillance as determinant of long-term survival in non-transplanted hepatocellular carcinoma patients 37
Hepatic encephalopathy increases the risk for mortality and hospital readmission in decompensated cirrhotic patients: a prospective multicenter study 35
The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints 34
Through-the-needle biopsy of pancreatic cystic lesions: stronger evidences of higher diagnostic yield compared with cytology 33
COSMIC-312: mounting immunotherapy enigmas for hepatocellular carcinoma 31
The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib 31
Reply 28
Telemedicine Is an Effective Tool to Monitor Disease Activity in IBD Patients in the COVID-19 Era: A Single Centre Experience Based on Objective Data 27
The relevance of noninvasive tools to assess fibrosis in non-alcoholic fatty liver disease 27
The price and value of therapeutic synergy in liver cancer 26
Balancing Efficacy and Tolerability of First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis 25
Risk profiling of hepatocellular carcinoma occurrence after eradication of hepatitis C virus with direct-acting antiviral agents 24
What is the benefit of prophylaxis to prevent HBV reactivation in HBsAg-negative anti-HBc-positive patients? Meta-analysis and decision curve analysis 23
Role of LI-RADS Indeterminate Observations in the Risk of Hepatocellular Carcinoma after HCV Eradication with Direct-Acting Antivirals 23
Initial uptake of durvalumab with or without tremelimumab for advanced hepatocellular carcinoma in routine clinical practice: Preliminary results of the international DT-real study 23
Clinical outcomes of MAFLD versus NAFLD: A meta-analysis of observational studies 20
Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept 20
Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib 20
Endothelial angiopoietin-2 overexpression in explanted livers identifies subjects at higher risk of recurrence of hepatocellular carcinoma after liver transplantation 19
Expert opinion vs. meta-analysis: To be or not to be? 18
Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma 18
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction 17
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab 16
Textbook Outcome After Trans-arterial Chemoembolization for Hepatocellular Carcinoma 15
Reply to: “irLI or not irLI: That is the question” 15
Evaluating the risk-benefit ratio of immunotherapy according to liver-functional reserve in advanced HCC: the dark side of the moon 14
Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs 14
Non-Invasive Diagnostic Tests for Portal Hypertension in Patients with HBV- and HCV-Related Cirrhosis: A Comprehensive Review 14
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours 14
Reliability of grading preoperative pancreatic neuroendocrine tumors on EUS specimens: a systematic review with meta-analysis of aggregate and individual data 13
Navigating the landscape of liver cancer management: Study designs in clinical trials and clinical practice 12
The Application of Large Language Models in Gastroenterology: A Review of the Literature 11
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis 11
Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study 10
Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinoma 9
Evaluating the predictive performance of the elderly patient calculator TIPS score in a North American cohort 8
null 3
null 3
Totale 3.633
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.873
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.873
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020136 0 0 0 0 0 0 0 0 52 34 40 10
2020/2021354 15 18 30 14 34 16 50 29 51 23 39 35
2021/2022534 50 36 16 17 5 14 10 158 70 32 32 94
2022/2023923 60 165 8 112 82 103 89 73 159 10 35 27
2023/2024550 24 54 36 43 19 153 59 17 17 29 32 67
2024/2025946 35 125 217 131 31 140 146 82 39 0 0 0
Totale 3.633